<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>29(10)</volume><submitter>Zhao C</submitter><pubmed_abstract>Hepatocellular carcinoma (HCC) is a malignant disease with an increasing incidence and a high mortality rate. Ferroptosis, a novel type of cell death, has been reported to be closely associated with the progression of HCC. The aim of our study was to construct a novel ferroptosis-related signature (nFRGs) for prediction of prognosis, immune features and drug sensitivity of HCC patients. Data were obtained from the TCGA, ICGC, GSE104580, CCLE and IMvigor210 datasets, and the least absolute shrinkage and selection operator (LASSO) was used to construct nFRGs. In addition, the analyses involved in prognoses, molecular function, stemness indices, somatic mutation, responses to immunologic therapy, efficacy of transcatheter arterial chemoembolization (TACE) therapy and drug sensitivity were per</pubmed_abstract><journal>Current oncology (Toronto, Ont.)</journal><pagination>6992-7011</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9601138</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A Novel Ferroptosis-Related Signature for Prediction of Prognosis, Immune Profiles and Drug Sensitivity in Hepatocellular Carcinoma Patients.</pubmed_title><pmcid>PMC9601138</pmcid><pubmed_authors>Tao J</pubmed_authors><pubmed_authors>Zhao C</pubmed_authors><pubmed_authors>Zhang Z</pubmed_authors></additional><is_claimable>false</is_claimable><name>A Novel Ferroptosis-Related Signature for Prediction of Prognosis, Immune Profiles and Drug Sensitivity in Hepatocellular Carcinoma Patients.</name><description>Hepatocellular carcinoma (HCC) is a malignant disease with an increasing incidence and a high mortality rate. Ferroptosis, a novel type of cell death, has been reported to be closely associated with the progression of HCC. The aim of our study was to construct a novel ferroptosis-related signature (nFRGs) for prediction of prognosis, immune features and drug sensitivity of HCC patients. Data were obtained from the TCGA, ICGC, GSE104580, CCLE and IMvigor210 datasets, and the least absolute shrinkage and selection operator (LASSO) was used to construct nFRGs. In addition, the analyses involved in prognoses, molecular function, stemness indices, somatic mutation, responses to immunologic therapy, efficacy of transcatheter arterial chemoembolization (TACE) therapy and drug sensitivity were per</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Sep</publication><modification>2026-06-21T03:08:57.629Z</modification><creation>2024-11-19T16:30:33.558Z</creation></dates><accession>S-EPMC9601138</accession><cross_references><pubmed>36290827</pubmed><doi>10.3390/curroncol29100550</doi></cross_references></HashMap>